Pịa ebe a ma ọ bụrụ na nke a bụ ntọhapụ mgbasa ozi gị!

Omicron Vaccine Development Strategy Ugbu a ekwuputala

Ọgwụ Everest na Providence Therapeutics (“Providence”) jikọtara ọnụ na-ekwupụta taa na ụlọ ọrụ ahụ amalitela ịrụ ọrụ na ụdị ọhụrụ nke ọgwụ mgbochi COVID-19 na-elekwasị anya na ụdị Omicron ọhụrụ.

Print Friendly, PDF & Email

Ndị ọkà mmụta sayensị sitere na ụlọ ọrụ abụọ ahụ enyochala usoro nke SARS-CoV-2 Omicron variant, usoro nje ahọpụtara, yana emepụta clone plasmid. Anyị na-atụ anya na enwere ike ibuga ọgwụ mgbochi ọhụrụ Omicron SARS-CoV-2 n'ime nnwale ụlọ ọgwụ n'ihe na-erughị ụbọchị 100.

"Anyị kwenyere na ọ dị mkpa ịmepụta ọgwụ ọhụrụ ngwa ngwa na nke ọma iji luso ụdị Omicron COVID-19 ọhụrụ ọgụ. Anyị na ndị na-ahụ maka njikwa ga-arụkọ ọrụ ọnụ ma chọọ nyocha ụlọ ọgwụ kwesịrị ekwesị na nnabata iwu iji weta ọgwụ mgbochi a n'ahịa ozugbo enwere ike. " Brad Sorenson, CEO nke Providence Therapeutics kwuru.

"Anyị na-atụ anya ịmepụta ọgwụ mgbochi Omicron ọhụrụ a ngwa ngwa na Providence, na iweta uru ọgwụ mgbochi a na mpaghara ndị nwere obere ohere na ọgwụgwọ ọgwụ mgbochi mRNA ugbu a karịsịa." kwuru Kerry Blanchard, MD, PhD, Onye isi nchịkwa nke ọgwụ Everest. 

Print Friendly, PDF & Email

Banyere chepụtara

Linda Hohnholz, onye editọ eTN

Linda Hohnholz na-ede ma na-edezi isiokwu kemgbe ọ malitere ọrụ ya. O tinyela obi uto nke a dika ebe Hawaii Pacific University, Chaminade University, Hawaii Discovery Center, ma ugbu a TravelNewsGroup.

Ahapụ a Comment